FDA Approves ORLADEYO, First Oral HAE Drug for Children
Interim data from APeX-P, the largest pediatric HAE prophylaxis study to date in patients aged 2 to under 12,...
Novabridge Reveals Promising Ragistomig Phase 1 Data at ESMO
In a Phase 1 expansion of ragistomig, a 4-1BB × PD-L1 bispecific, the 3 mg/kg every-six-weeks regimen delivered an...
Aardvark’s HERO Trial for Prader-Willi Doses First Patient
Enrollment remains on pace for a Q3 2026 topline readout in Aardvark Therapeutics’ Phase 3 HERO trial of ARD-101...
Promising Results for Samuraciclib in Advanced Breast Cancer
Samuraciclib plus fulvestrant delivered an overall response rate of 55% and a median progression-free survival of 14.5 months in...
Nucana Data Shows NUC-7738 Activity in Resistant Melanoma
In PD-1 inhibitor–resistant metastatic melanoma, NuCana’s NUC-7738 plus pembrolizumab produced two partial responses (one confirmed) and seven instances of...
Barinthus Bio Phase 1 Avalon Celiac Trial Update
In the single-ascending dose portion of the first-in-human AVALON trial (NCT06310291), VTP-1000 was well tolerated with no treatment-related serious...
What Happened to Accendatech’s Promising IPF Drug Trial?
Accendatech reported that in an exploratory cohort of idiopathic pulmonary fibrosis, 38% of evaluable patients (11 of 29) on...
20+ Orelabrutinib Studies Presented at ASH Annual Meeting
Post-cycle 6 in newly diagnosed primary CNS lymphoma treated with orelabrutinib, rituximab, and high-dose methotrexate, objective responses reached 89.5%...
Medicenna Reveals New MDNA11 Clinical Data in Live Webinar
Medicenna will unveil updated ABILITY-1 Phase 1/2 data for its long-acting IL-2 superkine MDNA11—both as monotherapy and in combination...
Praxis & FDA Align on Accelerated Pathway for SCN2A Drug
Praxis secured FDA agreement to convert EMBRAVE3, its registrational study of elsunersen in early-onset SCN2A developmental and epileptic encephalopathy,...